Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes

References

• CDC. National diabetes statistics report; 2017 [cited 2018 Mar 6]. Available from: http://www.diabetes.org/assets/pdfs/basics/cdc-statistics-report-2017.pdf.
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. (London, England). 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. (London, England). 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. (London, England). 2007;370:829–840.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association For The Study Of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S86–S104.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–2128.
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313–324.
   PubMed Web of Science ®Google Scholar
• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–970.
   PubMed Web of Science ®Google Scholar
• Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward AJ, O’Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the. U.S. Diabetes Care. 2002;25:476–481.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consnsus statement by the American Association of Clinical Endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24:91–120.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Introduction: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S1–S2.
   PubMed Web of Science ®Google Scholar
• Redbook Online®. Truven health. Wholesale acquisition cost [Internet] [cited 2015 Nov 12]. Available from: http://www.redbook.com/redbook/awp/.
   Google Scholar
• Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ. 2008;34:692–697.
   PubMed Web of Science ®Google Scholar
• Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151–173.
   PubMedGoogle Scholar
• Shao H, Zhai S, Zou D, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017;33:359–369.
   PubMed Web of Science ®Google Scholar
• Gu S, Mu Y, Zhai S, et al. Cost-effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China. PLoS One. 2016;11:e0165629.
   PubMed Web of Science ®Google Scholar
• Charokopou M, Vioix H, Eddowes LA, et al. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as triple therapy in combination with metformin and a sulphonylurea in the treatment of type 2 diabetes mellitus from a UK health care perspective. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A347.
   Web of Science ®Google Scholar
• Vega-Hernandez G, Wojcik R, Schlueter M. Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK. Diabetes Ther. 2017;8:513–530.
   PubMed Web of Science ®Google Scholar
• Sanchez-Covisa J, Capel M, Schmidt R, et al. The cost-effectiveness of dapagliflozin in combination with insulin for the treatment of type 2 diabetes mellitus (T2DM) in Spain. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A350.
   PubMed Web of Science ®Google Scholar
• van Haalen HGM, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34:135–146.
   PubMed Web of Science ®Google Scholar
• Charokopou M, Vioix H, Verheggen BG, et al. Economic assessment of delaying insulin treatment through the use of newer anti-diabetic agents, dapagliflozin (Forxiga(R)) and exenatide (Bydureon(R)), both as add-on to metformin; a cost-effectiveness analysis from a UK NHS perspective. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A344–5.
   PubMed Web of Science ®Google Scholar
• Charokopou M, Vioix H, Verheggen B, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as monotherapy in the treatment of type 2 diabetes mellitus from a UK health care perspective. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A347.
   Web of Science ®Google Scholar
• Chakravarty A, Rastogi M, Dhankhar P, et al. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. J Med Econ. 2018;21:497–509.
   PubMed Web of Science ®Google Scholar
• Charokopou M, Vioix H, Verheggen BG, et al. Dapagliflozin (Forxiga(R)) versus glipizide as add-on therapies in type 2 diabetes mellitus (T2DM); an update of the cost-effectiveness based on long-term clinical evidence from UK NHS perspective. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A343.
   Web of Science ®Google Scholar
• Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med. 2015;32:890–898.
   PubMed Web of Science ®Google Scholar
• Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9:39–47.
   PubMed Web of Science ®Google Scholar
• Abad Paniagua EJ, Casado Escribano P, Fernandez Rodriguez JM, et al. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain]. Aten primaria. 2015;47:505–513.
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Tentolouris N, Kourlaba G, et al. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Invest. 2016;36:649–659.
   PubMed Web of Science ®Google Scholar
• Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res. 2015;15:496.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Ramírez de Arellano Serna A, Mezquita-Raya P, Vega-Hernandez G, et al. Liraglutide versus dapagliflozin for the treatment of patients with type-2 diabetes mellitus in Spain: a cost-effectiveness analysis. Value Heal. [Internet]. 2016;19:A674.
   Web of Science ®Google Scholar
• Bacon T, Willis M, Johansen P, et al. The cost-effectiveness of canagliflozin verse insulin-secretagogues (sulphonylureas) or insulin in patients with type 2 diabetes mellitus (T2DM) as an add-on to metformin in Ireland. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A346.
   PubMed Web of Science ®Google Scholar
• Szmurlo D, Drzal R, Plisko R, et al. Cost effectiveness evaluation of canagliflozin in combination with metformin and sulfonylurea in comparison to NPH insulin in the treatment of type 2 diabetes mellitus in Poland. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A351.
   PubMed Web of Science ®Google Scholar
• Neslusan C, Teschemaker A, Johansen P, et al. Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico. Value Heal Reg Issues. 2015;8:8–19.
   PubMedGoogle Scholar
• Pititto L, Neslusan C, Teschemaker AR, et al. Cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as add-on to metformin plus sulfonylurea in patients with type 2 diabetes mellitus (T2DM) in Brazil. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2015;18:A864.
   PubMed Web of Science ®Google Scholar
• Bacon T, Willis M, Johansen P, et al. The cost-effectiveness of canagliflozin verse liraglutide in patients with type 2 diabetes (T2DM) failing to achieve glycaemic control on metformin monotherapy in Ireland. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A345.
   Web of Science ®Google Scholar
• Sabapathy S, Neslusan C, Yoong K, et al. Cost-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in type 2 diabetes in Canada. J Popul Ther Clin Pharmacol. 2016;23:e151–68.
   PubMed Web of Science ®Google Scholar
• Troelsgaard A, Pitcher A, Granados D, et al. The cost-effectiveness of canagliflozin compared with liraglutide in patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea in France. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A346–7.
   PubMed Web of Science ®Google Scholar
• Szmurlo D, Drzal R, Plisko R, et al. Cost effectiveness evaluation of canagliflozin in combination with metformin in the treatment of type 2 diabetes mellitus in Poland. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2014;17:A346.
   PubMed Web of Science ®Google Scholar
• Neslusan C, Teschemaker A, Willis M, et al. Cost-effectiveness analysis of canagliflozin 300 mg versus dapagliflozin 10 mg added to metformin in patients with type 2 diabetes in the United States. Diabetes Ther. 2018;9:565–581.
   PubMed Web of Science ®Google Scholar
• Schroeder M, Johansen P, Willis M, et al. The cost-effectiveness of canagliflozin (CANA) versus dapagliflozin (DAPA) 10mg and empagliflozin (EMPA) 25mg in patients with type 2 diabetes mellitus (T2DM) as monotherapy in the United Kingdom. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2015;18:A607.
   PubMed Web of Science ®Google Scholar
• Kansal A, Reifsnider O, Lee J, et al. Cost-effectiveness analysis of empagliflozin compared with canagliflozin or Standard of Care (SoC) in patients with T2DM and established cardiovascular (CV) disease. Diabetes. [Internet]. 2018;67. Available from http://diabetes.diabetesjournals.org/content/67/Supplement_1/1294-P.abstract
   Google Scholar
• Aguiar-Ibáñez R, Palencia R, Kandaswamy P, et al. Cost-effectiveness of empagliflozin (Jardiance®) 10 mg and 25 mg administered as an add-on to metformin and sulfonilurea (Met+Su) Compared to other sodium-glucose co-transporter 2 inhibitors (SGLT2Is) in patients with type 2 diabetes mellitus (T2DM). Value Heal. [Internet]. 2014;17:A351.
   PubMed Web of Science ®Google Scholar
• Aguiar-Ibáñez R, Palencia R, Kandaswamy P, et al. Cost-effectiveness of empagliflozin (Jardiance®) 10 mg and 25 mg administered as an add-on to metformin compared to other sodium-glucose co-transporter 2 inhibitors (SGLT2Is) for patients with type 2 diabetes mellitus (T2DM) in the UK. Value Heal. [Internet]. 2014;17:A350–A351.
   PubMed Web of Science ®Google Scholar
• Henkhaus LE, Hay JW. Cost effectiveness of empagliflozin/linagliptin as 2nd-line therapy for adults with type 2 diabetes. Value Heal. [Internet]. 2016;19:A202–A203.
   PubMed Web of Science ®Google Scholar
• Nguyen E, Coleman CI, Nair S, et al. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018;32:210–215.
   PubMed Web of Science ®Google Scholar
• Gourzoulidis G, Tzanetakos C, Ioannidis I, et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece. Clin Drug Invest. 2018;38:417–426.
   PubMed Web of Science ®Google Scholar
• Pawlik D, Wójcik R, Zawodnik A, et al. Cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus at high cardiovascular risk in Poland. Value Heal. [Internet]. 2017;20:A478.
   Web of Science ®Google Scholar
• Daacke I, Kandaswamy P, Tebboth A, et al. Cost-effectiveness of empagliflozin (jardiance) in the treatment of patients with type 2 diabetes mellitus (T2DM) in the UK based on EMPA-REG outcome data. Value Heal. [Internet]. 2016;19:A673.
   Web of Science ®Google Scholar
• Mettam SR, Bajaj H, Kansal AR, et al. Cost effectiveness of empagliflozin in patients with T2DM and high CV risk in Canada. Value Heal. [Internet]. 2016;19:A674.
   Web of Science ®Google Scholar
• Iannazzo S, Mannucci E, Reifsnider O, et al. Cost-effectiveness analysis of empagliflozin in the treatment of T2D with previous cardiovascular disease in Italy. Value Heal. [Internet]. 2017;20:A480–A481.
   Web of Science ®Google Scholar
• Oksuz E, Malhan S, Kamaci E, et al. Cost-effectiveness of empagliflozin (jardiance®) in the treatment of patients with type 2 diabetes mellitus (T2DM) in Turkey based EMPA-REG outcome data. Value Heal. [Internet]. 2017;20:A479.
   Web of Science ®Google Scholar
• Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome study. Diabetes Care. 2016;39:717–725.
   PubMed Web of Science ®Google Scholar
• Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian pharmaceutical benefits scheme. JAMA. 2000;283:2116–2121.
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454–465.
   PubMed Web of Science ®Google Scholar